Precipice Design Reimagines NIOX VERO® Asthma Detection and Management System

The reinterpretation of the Gold Standard FeNo testing device features an adapted UI, larger screen, reconsidered ergonomics and contemporary industrial design offering additional 

options to asthma patients and clinicians. 

London, UK, 9 December 2019: Precipice Design, a strategic consultancy specialising in healthcare related product, brand and experience design, is proud to announce its work with specialist pharmaceutical company, Circassia, to reimagine the NIOX VERO®, a ‘gold standard’ point-of-care medical device which detects nitric oxide levels, a marker of airway inflammation, in patients’ breath, to help diagnose and manage asthma.

Circassia challenged Precipice Design to further develop the established and class leading NIOX VERO® with the aim of offering additional choices to patients and clinicians who are seeking enhancements to the current device which will build on already superior patient usability and clinician efficiency. 

Miles Hawley, CEO at Precipice Design, commented: “As a pioneering device in its field of respiratory medicine, the current NIOX VERO® model is widely valued by medical professionals as the gold standard in FeNo testing. Our task was to further enhance the clinical and patient experience, by providing enhanced product and UI features.”

Precipice Design worked closely with Circassia’s in-house R&D team transforming the existing device to become the NIOX VERO® Plus. The updated product has a new carry handle feature and reworked access to the breathing handle. In addition, the screen is larger, and the UI adapted, offering an enhanced user-friendly experience.

Miles Hawley continued: “During research conducted by our team across Europe, the US and China we iteratively stress-tested all physical and digital aspects of the new NIOX VERO® Plus design, enhancing the original device and reimagining the UI. Its virtually wordless design and new ‘dashboard’ led visual aesthetic has been developed to be used across Circassia’s key global markets. Patients and clinicians can choose between universal graphics, such as a balloon, accelerator style gauge or a floating feather, to guide their breathing into the device, further improving patient’s and clinician’s user experience, demonstrating the impactful new design undertaken by the consultancy.”

The new NIOX VERO® Plus device was unveiled at the European Respiratory Symposium (ERS) which took place in Madrid 28th September - 2nd October 2019.

For further information on Precipice Design, please visit: www.precipice-design.com

About Precipice Design:

Precipice Design is a London-based consultancy with multiple design awards from iF, A’Design and Spark. They create future product, brand and packaging solutions – from concept to commercialisation – by aligning human needs and desires with emerging science and technology. 

Major clients include Bang & Olufsen, LG, Kohler, Molecular Health, Mundipharma & Sanofi. www.precipice-design.com 

About NIOX®:

NIOX® is the leading point-of-care system for measuring fractional exhaled nitric oxide (FeNO), an important biomarker of the major underlying cause of asthma, type 2 airway inflammation. NIOX® is used around the world to improve asthma diagnosis and management. Circassia sells NIOX® directly in the United States, China, UK, Germany and Italy and through its international network of partners in more than 40 further countries.